Skip to content

Mark.Pershouse

Profile

Name: Mark Pershouse

Title: Associate Professor

Email: mark.pershouse@umontana.edu

Phone: 406-243-4769

Office: SB 281

Background

After completing undergraduate work in biology at Texas Tech University in Lubbock, Dr. Pershouse earned a Ph.D. in Biomedical Sciences under the guidance of Professor Elton Stubblefield at the University of Texas Graduate School of Biomedical Sciences in Houston. Following a postdoctoral fellowship at the M.D. Anderson Cancer Center under the supervision of Professor Peter Steck, and a brief postdoctoral associate position at Baylor College of Medicine with Drs Craig Chinault and Allan Bradley, he joined the faculty at The University of Montana as a Research Assistant Professor in September of 2000, was promoted to Assistant Professor in 2002, and to Associate Professor in 2007.

 

Research Statement

The Pershouse lab focuses on the mechanisms utilized by cancer cells to evade normal growth control. His lab has been studying the role of tumor suppressor genes in various human cancer models. Due to our proximity to Libby, Montana, there is a great deal of interest in mesotheliomas, a tumor tightly linked to asbestos exposure. These studies aim to expand our ability to detect tumor formation at an earlier, more treatable stage, as well as to provide scientists with better targets for effective therapeutics. Dr. Pershouse was a member of one of the competing labs that discovered the PTEN tumor suppressor gene, a gene altered in a high percentage of human tumors.

The laboratory has also begun a new study aimed at providing oncologists with vital information on American Indian genetics that will allow the prediction of chemotherapy drug response. This technology is becoming widely used in the general population, but several key pieces of data are necessary for application in Indian country. This is one of the first studies to target American Indian pharmacogenetics in the country.

 

Publications

Leyva FJ, Pershouse MA, Holian A. Modified low density lipoproteins binding requires a lysine cluster region in the murine macrophage scavenger receptor class A type II. Mol Biol Rep. 2009 Sep 23. [Epub ahead of print]

Leyva FJ, Pershouse MA. Quantitative and qualitative methods using fluorescence microscopy for the study of modified low density lipoproteins uptake. Scanning. 2009 Sep 18. [Epub ahead of print]

Pershouse M.A., Smartt A.M., Schwanke C.M., and Putnam E.A. Differences in gene expression profiles from asbestos-treated SPARC-null and wild type mouse lungs. Genomics 2009 Aug;94(2):101-9. Epub 2009 May 13.

Bunderson Schelvan M., Erbe A., Schwanke C.M., and Pershouse M.A. Suppression of the MDM4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to UV exposure. Accepted with revisions, Environmental and Molecular Mutagenesis 2009 May 26. [Epub ahead of print]

Pershouse M.A., Bunderson Schelvan M., Schwanke C.M. (2009) Omics Information Resource, a chapter from Information Resources in Toxicology (4th Edition) Edited by Wexler, Hakkinen, Mohapatra & Stoss, National Library of Medicine. Published by Elsevier.

Pershouse M.A., Bunderson Schelvan M., Erbe A., Schwanke C.M., Putnam E.A. (2009) Toxicoinformatics Information Resource, a chapter from Information Resources in Toxicology (4th Edition) Edited by Wexler, Hakkinen, Mohapatra & Stoss, National Library of Medicine. Published by Elsevier.

Putnam E.A., Smartt A., Brezinski M., Groves A., Schwanke C.M., and Pershouse M.A. (2008) Gene expression changes after exposure to Six-mix in a mouse model. Journal of Immunotoxicology 5(2): 139-144.

Larson S.J., Putnam E.A., Schwanke C.M., and Pershouse M.A. (2007) Potential surrogate markers for gamma-hydroxybutyrate administration may extend the detection window from 12 to 48 hours. Journal of Analytical Toxicology 31:15-22.

Pershouse M.A., Heivly S., and Girtsman T. (2006) The role of SV40 in malignant mesothelioma and other human malignancies. Inhalation Toxicology 18:995-1000.

Misra A., Pellarin M., Hu L., Kunwar S., Perhouse M., Lamborn K.R., Deen D.F., Feuerstein B.G. (2006) Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes Chromosomes Cancer 45(1):20-30.

Pfau J.C., Pershouse M.A., and Putnam E.A. (2006) Conference Summary. Directions and Needs in Asbestos Research: New Insights. Inhalation Toxicology 18(12):919-923.

Brown J.M., Schwanke C.M., Pershouse M.A., Pfau J.C., and Holian A. (2005) Effects of Rottlerin on Silica-Exacerbated Systemic Autoimmune Disease in New Zealand Mixed Mice Am J Physiol Lung Cell Mol Physiol 2005 Dec;289(6):L990-8. Epub 2005 Jul 22.

Brown J.M., Pfau J.C., Pershouse M.A., and Holian A. (2004) Silica, apoptosis, and autoimmunity. Journal of Immunotoxicology 1(3,4):177-187.

Kruzelock R.P., Cuevas B.D., Wiener J.R., Xu F.J., Yu Y., Pershouse M.A., Lovell M.M., Killary A.M., Mills G.B., and Bast R.C. (2000) Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(55) 6277-6285.

Pershouse M.A.*, Li J.*, Brundage E., Di W., Bradley A., and Chinault A.C. (2000) (*first authors equal) A 3 cM BAC Contig from Mouse Chromosome 11 surrounding BRCA1 in the Human 17 Syntenic Region. Genomics 69(1): 139-142.

Steck P.A., Lin H., Langford L.A., Jasser S.A., Koul D., Yung W.K., and Pershouse M.A. (1999) Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer. 24(2):135-43.

Lin H., Bondy M.L., Langford L.A., Hess K.R., Delclos G.L., Wu X., Chan W., Pershouse M.A., Yung W.K., and Steck P.A. (1998) Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clinical Cancer Research. 4(10):2447-54.

Hadi A.H., Pershouse M.A., Jasser S., Hong Y.K., Yung W.K.A., and Steck P.A. (1998) Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. Journal of NeuroVirology 4: 217-226.

Teng D.H.-F., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen B., Vinson V.L., Gumpper L.E., Ellis L., El-Naggar A., Frazier M., Jasser S., Langford L., Lee J., Mills G.B., Pershouse M.A., Pollack R.E., Tornos C., Troncoso P., Yung W.K.A., Fujii G., Berson A., Bookstein R., Bolen J.B., Tavtigian S.T., and Steck P.A. (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Research 57: 5221-5225.

Pershouse M.A., Stubblefield E., Hadi A., Pereira-Smith O., Yung W.K.A., and Steck P. (1997) Suppression of transformation and tumorigenicity after transfer of chromosome 4 into a human glioblastoma multiforme cell line. Genes, Chromosomes, and Cancer 20:260-267.

Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlun B., Teng D.H.F., and Tavtigian S.V. (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15: 356-362.

Hadi Ligon A., Pershouse M.A., Jasser S.A., Yung W.K.A., and Steck P.A. (1997) Identification of a novel gene product ,RIG, that is down-regulated in human glioblastoma. Oncogene 14:1075-1081.

Pershouse M.A., el Naggar A., Hurr K., Yung W.K.A., and Steck P. (1997) Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene 14:369-373.

Akeyson E.W., McCutcheon I.E., Pershouse M.A., Steck P.A., and Fuller G.N. (1996) Primitive neuroectodermal tumor of the median nerve. Case report with cytogenetic analysis. Journal of Neurosurgery 85:163-169.

Fueyo J., Gomez-MAnzano C., Yung W.K.A., Zhang W., Lee P.S.Y., Majumder S., Pershouse M.A., Levin V.A., and Kyritsis A.P. (1995) A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Molecular and Cellular Probes 9:465-466.

Steck P.A., Ligon A.H., Cheong P., Yung W.K.A., and Pershouse M.A. (1995) Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes, Chromosomes, and Cancer, 12:255-261.

Pershouse M.A., Stubblefield E., Hadi A., Killary A., Yung W., and Steck P. (1993) Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Research 53: 5043-5050.

Stubblefield E., and Pershouse M.A. (1992) The direct formation of microcells from mitotic cells for use in chromosome transfer. Somatic Cell and Molecular Genetics 18(6): 485-491.

Brinkley B., Zinkowski R., Mollon W., Davis F., Pisegna M., Pershouse M.A., and Rao P. (1988) Movement and segregation of kinetichores experimentally detached from mammalian chromosomes. Nature 336: 251-254.

Johnson T., Katz R., and Pershouse M.A. (1988) Flow cytometry applications in cytopathology. Analytical and Quantitative Cytology. 10(6): 423-458.

Barlogie B., Alexanian R., Pershouse M.A., Smallwood L., and Smith L. (1985) Cytoplasmic immunoglobulin content in multiple myeloma. Journal of Clinical Investigation. 76:765-769.

Kantarjian H., Barlogie B., Pershouse M.A., Swartzendruber D., Keating M., McCredie K., and Freireich E. (1985) Preferential expression of double-stranded ribonucleic acid (DSRNA) in tumor vs. normal cells - biologic and clinical implications. Blood 66(1):39-46.


The University of Montana-Missoula
The Department of Biomedical & Pharmaceutical Sciences
32 Campus Drive, Skaggs 395
Missoula, MT 59812-1552
Phone 406.243.4767 Fax: 406.243.5228
Email: biomed@umontana.edu

glqxz9283 sfy39587p06